echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Scientists have developed a new type of bacterial therapy to improve the condition of 2/3 patients with eczema

    Scientists have developed a new type of bacterial therapy to improve the condition of 2/3 patients with eczema

    • Last Update: 2021-07-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

     This new treatment method that uses symbiotic microorganisms to protect the skin is safe within 7 days

     I believe that many people have suffered from dermatitis, especially atopic dermatitis (AD)
    Atopic dermatitis, also known as atopic eczema, is a common chronic, recurrent, and inflammatory skin disease.
    The clinical manifestations are mainly dry skin, eczema-like rash, and severe itching
    At present, the clinical treatment is mainly through conventional external medication, but it can only be temporarily relieved, and it is easy to relapse, and the effect is not satisfactory

     The pathophysiology of atopic dermatitis involves many factors, including host genetics, changes in skin barrier function, and immune abnormalities
    Atopic dermatitis is usually characterized by the overgrowth of Staphylococcus aureus, which then triggers proteolytic destruction of the epidermal barrier and immune disorders
    Unfortunately, attempts to treat AD with systemic and topical antibiotics did not directly kill surface bacteria and improve skin inflammation
    Previous studies have confirmed that some strains of skin symbiotic coagulase-negative staphylococci (CoNS) produce various types of bacteriocins, which can selectively inhibit non-resident pathogenic bacteria on the skin surface, such as Staphylococcus aureus, group A Streptococcus and Escherichia coli

     On February 22, 2021, the Richard L.
    Gallo research team of the University of California made the latest progress, and published a publication titled "Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized" in the journal Nature Medicine.
    "Clinical trial" article, reporting on the development of human skin symbiotic microorganisms for the treatment of atopic dermatitis (AD) and their use in phase 1 randomized clinical trials

     First, the research team conducted selection and preclinical testing of symbiotic bacteria that are beneficial to human skin
    The researchers screened more than 8,000 CoNS bacteria from the skin of healthy subjects, identified several strains that have the ability to inhibit the growth of Staphylococcus aureus in vitro, and further evaluated other characteristics
    The results showed that a strain of human streptococcus (ShA9) was selected in the AD11 mouse model, and its survival rate against Staphylococcus aureus was 99.
    ShA9 lotion also improved local erythema and inhibited AD inflammation-related Several genes, including Il-4, Il-13, Tslp, Cxcl2, Il-17a, and Il-22
    The risk of bacteremia with topical ShA9 is also lower

     Subsequently, the researchers evaluated the safety of ShA9 on the skin of participants with AD, and designed a randomized, double-blind phase 1 human clinical trial to better understand the mechanism of action and explore the effects of ShA9 on humans.
    Potential therapeutic effects on the skin

     The included population was adults with moderate to severe AD on the ventral arm (n = 54), and patients with positive Staphylococcus aureus cultures.
    Participants were randomized at a ratio of 2:1.
    36 received ShA9 and 18 received alone Placebo, ShA9 or placebo was applied topically to the ventral side of the forearm twice a day for 7 days
    Obtain clinical evaluation and skin swabs during the treatment period 1 hour before and after the first application on day 1.
    On the 4th and 7th day of treatment, the swabs are also collected and performed approximately 30 days after the last administration Telephone follow-up evaluation

     The results of the trial showed that participants who received ShA9 had fewer AD-related adverse events.
    There was no significant difference in the severity of eczema in all participants who received ShA9.
    However, when the secondary endpoint was observed and reached, Staphylococcus aureus Significantly reduced, ShA9 DNA increased
    Some of the participants’ Staphylococcus aureus strains were not directly killed by ShA9, but the mRNAs expressing Staphylococcus aureus toxin in all strains were inhibited
    In general, two-thirds of the participants had improved symptoms, and the severity of local eczema had improved
    These observations prove the safety and potential benefits of bacterial therapy for AD

     In short, the researchers proposed that the best treatment for AD is to restore the epidermal barrier defect while suppressing the cause of inflammation
    The data of the current study shows that this new treatment method that uses symbiotic microorganisms to protect the skin is safe within 7 days
    (Biological Exploration)

     Reference materials:


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.